DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1948)

Heart Failure | Current Treatment | Detailed, Expanded Analysis - Chronic Heart Failure - Reduced Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US

Heart Failure | Current Treatment | Detailed, Expanded Analysis - Chronic Heart Failure - Reduced Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well-established with a wealth of supporting evidence from clinical trials. ACE inhibitors or AIIRA/ARBs, beta blockers, and loop diuretics are typically used in first-line treatment of HFrEF patients. Given the heavily genericized nature of the market, branded agents, such as Novartis’s Entresto and Amgen’s Corlanor, have had difficulty establishing a foothold; however, use of Entresto has been steadily growing since its launch in 2015. This HFrEF treatment algorithm offers insight into the U.S. prescribing patterns in this CHF subpopulation.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HFrEF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFrEF patients?
  • How have Entresto and Corlanor been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of HFrEF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of HFrEF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated HFrEF patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis - Chronic Heart Failure - Reduced Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US
    • Treatment Algorithms: Claims Data Analysis | Chronic Heart Failure with Reduced Ejection Fraction | US | May 2019

Already a Client? Log in to access this report.

  • Pub Date: May 2019
  • Author(s): Dwaipayan Chatterjee, M.Pharm
  • Dwaipayan Chatterjee is an Analyst in the Cardiovascular, Metabolism Renal and Hematology disease team at Decision Resources Group. He holds a degree with specialization in Pharmaceutical Chemistry from Birla Institute of Technology & Science, Pilani, Rajasthan, India. Prior joining DRG, he worked as an Equity Analyst for the Healthcare sector with Market Realist working on competitive intelligence and analysis of pharmaceutical financial data. He also worked as a market research analyst for Mordor Intelligence with experience of market sizing, forecasting, and analyzing market dynamics.

Purchase Report

Recent reports:
You may also be interested in: